Report cover image

Decentralized Clinical Trials Market - 2025-2033

Publisher DataM Intelligence 4Market Research LLP
Published Jan 06, 2026
Length 180 Pages
SKU # DTAM21021012

Description

DECENTRALIZED CLINICAL TRIALS MARKET SIZE

Decentralized Clinical Trials Market Size reached US$ 8.68 Billion in 2024 and is expected to reach US$ 29.90 Billion by 2033, growing at a CAGR of 14.8% during the forecast period 2025-2033.

DECENTRALIZED CLINICAL TRIALS MARKET OVERVIEW

The decentralized clinical trials market is undergoing rapid transformation, driven by technological innovation, shifting regulatory landscapes, and growing stakeholder investment. Challenges persist, particularly in areas such as regulatory standardization and data security, but opportunities abound. Organizations that invest in robust digital infrastructures, AI-driven analytics, and patient-centric engagement models are well-positioned to capture market share and redefine clinical research paradigms over the next decade.

EXECUTIVE SUMMARY

source: DataM IntelligenceFor more details on this report – Request for Sample (https://www.datamintelligence.com/download-sample/decentralized-clinical-trials-market)

DECENTRALIZED CLINICAL TRIALS MARKET DYNAMICS: DRIVERS & RESTRAINTS

THE RISING TECHNOLOGICAL ADVANCEMENTS IN DECENTRALIZED CLINICAL TRIALS ARE SIGNIFICANTLY DRIVING THE MARKET GROWTH

Companies like Medidata, Medable, and other major and emerging players have integrated AI-software solutions, Bluetooth-enabled ECG patches, continuous glucose monitors, and activity trackers into their DCT platforms. Instead of visiting a clinic for vitals or an ECG, patients simply wear a small patch (e.g., BioTelemetry’s Mobile Cardiac Outpatient Telemetry device) that streams heart-rate data in real-time to a centralized dashboard. Real-time physiological monitoring means faster safety signals, fewer on-site visits, and higher patient compliance. Trials for chronic conditions no longer require weekly clinic visits, patients can transmit data from home.

For instance, in November 2024, Medable Inc., a leading provider of clinical development technology, announced Medable AI, generative AI (https://www.datamintelligence.com/research-report/generative-ai-market) capabilities that help sponsors and clinical research organizations (CROs) build digital and decentralized trials faster with complete visibility and control over technology setup. Medable is the first to incorporate generative AI in the study build process, ultimately driving the industry to a breakthrough, one-day study startup.

Moreover, Science 37 offers a virtual trial operating system that integrates secure video calls, eConsent, and ePRO (electronic patient-reported outcomes) all in one place. During the COVID-19 pandemic, Pfizer used a telemedicine (https://www.datamintelligence.com/research-report/telemedicine-market) approach for its COVID vaccine booster study participants could be screened, consented, and followed up entirely via video call, with the investigational product shipped directly to their homes. By replacing in-person site visits with video visits (and mobile nursing visits, when necessary), sponsors reduce geographic barriers, speed up recruitment, and improve retention.

DATA PRIVACY AND SECURITY CONCERNS ARE HAMPERING THE GROWTH OF THE DECENTRALIZED CLINICAL TRIALS MARKET

In a traditional, site‐centric trial, data is largely generated and stored within a controlled hospital or research center. In decentralized clinical trials, however, data streams in real time from smartphones, wearable sensors (https://www.datamintelligence.com/research-report/wearable-sensor-market) (e.g., continuous glucose monitors, ECG patches), home‐visit nurses’ tablets, local laboratories, and cloud‐based EDC (electronic data capture) systems, which can lead to data breaches, further hampering the market growth.

For instance, according to the HIPAA Journal, in 2024, the protected health information of 276,775,457 individuals was exposed or stolen. On average, that is 758,288 records per day. In March 2025, 1,754,097 individuals had their protected health information exposed, stolen, or impermissibly disclosed in a healthcare data breach.

DECENTRALIZED CLINICAL TRIALS MARKET SEGMENT ANALYSIS

The global decentralized clinical trials market is segmented based on study type, component, therapeutic area, end-user, and region.

THE ONCOLOGY SEGMENT FROM THE THERAPEUTIC AREA IS EXPECTED TO HOLD 23.15% OF THE MARKET SHARE IN 2024 IN THE DECENTRALIZED CLINICAL TRIALS MARKET

According to the World Health Organization (WHO), over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Thus, rising cancer cases increase the need for further oncology trials, which often require continuous monitoring and long-term follow-up to assess the efficacy and safety of treatments. There is a rising oncology clinical trials, and many researchers are choosing the decentralized oncology trials, which further accelerates the segment’s growth.

For instance, in May 2025, Researchers at the Ohio State University Comprehensive Cancer Center (OSUCCC) are enrolling patients with advanced pancreatic cancer in a Phase II study of Incyte's Pemazyre (pemigatinib). Patients in this trial will be able to do all the tests and follow-ups to track their outcomes on the drug through community providers and via telemedicine, a fully decentralized approach that hasn't been widely embraced by drugmakers and researchers.

Decentralized clinical trials facilitate remote monitoring through wearable devices and telemedicine, enabling oncologists to observe changes in real time without the patient needing to make frequent clinic visits. For instance, in February 2023, the Nova Scotia Health Innovation Hub selected Medable’s decentralised clinical trial (DCT) platform to improve care accessibility for remote oncology patients in rural Nova Scotia, Canada. Patients can use Total Consent Management and Televisit solutions, plus other services from Medable, to speak with a physician from their home. Additionally, the new strategy is expected to empower primary care providers to be more involved with their patients after trials through a shared care model, which will be supported by decentralized clinical trial technologies.

DECENTRALIZED CLINICAL TRIALS MARKET GEOGRAPHICAL ANALYSIS

NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL DECENTRALIZED CLINICAL TRIALS MARKET WITH A 43.02% SHARE IN 2024

North America, especially the United States, has been a leader in pioneering new clinical trial models, with early adopters of decentralized clinical trial technologies making significant strides in remote patient monitoring, virtual visits, e-consent, and mobile health tools.

For instance, in November 2024, Medable Inc. released Medable AI, generative AI capabilities that help sponsors and clinical research organizations (CROs) build digital and decentralized trials faster with complete visibility and control over technology setup. Medable is the first to incorporate generative AI in the study-build process, ultimately driving the industry to a breakthrough, one-day study startup. Medable AI, integrated with Medable Studio, automates repetitive, time-intensive manual tasks to decrease time to First Patient In (FPI) for digital and decentralized clinical trials, dramatically accelerating study startup.

North America hosts a disproportionate share of large pharmaceutical and biotechnology headquarters. These companies are already running thousands of site-based trials, can readily convert portions of their portfolios to decentralized formats. For instance, Pfizer and Roche both piloted decentralized clinical trials modules (eConsent, direct‐to‐patient drug shipments, remote safety monitoring) in late 2023, taking advantage of U.S. infrastructure to execute these modules more swiftly than their non-U.S. peers.

ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN THE DECENTRALIZED CLINICAL TRIALS MARKET, HOLDING 21.07% OF THE MARKET SHARE

Asia Pacific is home to a vast and diverse population, with over 4.83 billion people across the region. This diverse population, especially in countries like China and India, presents significant opportunities for clinical trials that benefit from both a high volume of potential participants and varied demographics.

Clinical trials in the Asia Pacific are often more cost-effective compared to Western regions. For instance, according to the Clinical Leader, clinical trials in APAC countries cost 30%-40% less than in other regions, making the area very attractive to pharmaceutical and biotech companies. Lower costs of healthcare, patient recruitment, and infrastructure mean that pharmaceutical companies and contract research organizations (CROs) can run decentralized clinical trials at reduced costs. This makes it an attractive option for both global pharmaceutical companies and local biotech firms.

DECENTRALIZED CLINICAL TRIALS MARKET TOP COMPANIES

Top companies in the decentralized clinical trials market include ICON plc (https://www.iconplc.com/solutions/decentralised-clinical-trials), Parexel International Corporation, Laboratory Corporation of America Holdings, Medpace, Inc., Science 37, THREAD, Inc., Curebase (https://www.curebase.ai/resources/articles/decentralized-clinical-trial-company-buyers-guide), Castor, IQVIA Inc., and Medable Inc., among others.

EMERGING PLAYERS

The emerging players in the decentralized clinical trials market include Veeva Systems Inc., PRAXIS, Advarra, The Emmes Company, LLC, and Syneos Health, among others.

KEY DEVELOPMENTS

• In May 2025, ABM Respiratory Care, an innovator in respiratory therapy solutions, announced the initiation of a multi-center home care study in collaboration with Delve Health, a trailblazer in decentralized clinical trial technology, to evaluate the impact of its BiWaze Clear System in patients living with bronchiectasis. The study will assess how the BiWaze Clear System affects respiratory health over six months.
• In October 2024, Adaptive Research, a clinical trial site organization dedicated to democratizing clinical trials, announced its participation in a groundbreaking decentralized study for Parkinson’s Disease sponsored by PhotoPharmics Inc. California Movement Disorders Center, part of Adaptive Research’s network, will serve as a site for PhotoPharmics’ LIGHT-PD trial, testing the efficacy of Celeste Specialized Phototherapy in treating Parkinson’s symptoms.
• In August 2024, Walgreens and the Biomedical Advanced Research and Development Authority (BARDA) announced a strategic partnership to increase innovation in decentralized clinical trials as part of the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) program. The program is designed to strengthen U.S. decentralized clinical research capabilities to support the development of U.S. Food and Drug Administration (FDA)-regulated products, enhance clinical innovation to execute more efficient and relevant clinical research, and evaluate other medical countermeasures in real-world environments that may be used in a public health emergency.

MARKET SCOPE

Metrics Details
CAGR 14.8%
Market Size Available for Years 2022-2033
Estimation Forecast Period 2025-2033
Revenue Units Value (US$ Bn)
Segments Covered Study Type Interventional Trials, Observational Trials, Expanded Access Trials, Others
Component Software Solutions, Hardware Solutions
Therapeutic Area Oncology, Cardiovascular Diseases, Infectious Diseases, Respiratory Diseases, Neurology, Rare Diseases, Metabolic Disorders, Others
End-User Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, Others
Regions Covered North America, Europe, Asia-Pacific, South America, and the Middle East & Africa

The global decentralized clinical trials market report delivers a detailed analysis with 62 key tables, more than 53 visually impactful figures, and 178 pages of expert insights, providing a complete view of the market landscape.

Table of Contents

180 Pages
1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
3. Market Highlights and Strategic Takeaways
3.1. Key Trends and Future Projections
4. Snippet by Study Type
4.1. Snippet by Component
4.2. Snippet by Therapeutic Area
4.3. Snippet by End-User
4.4. Snippet by Region
5. Dynamics
5.1. Impacting Factors
5.1.1. Drivers
5.1.1.1. Rising Technological Advancements in Decentralized Clinical Trials
5.1.1.2. Enhanced Patient Diversity & Access
5.1.1.3. Data-Driven Adaptive Study Design
5.1.2. Restraints
5.1.2.1. Data Privacy and Security Concerns
5.1.2.2. Fragmentation in Technology Ecosystem
5.1.2.3. Complexity in Global Compliance & Data Localization Laws
5.1.3. Opportunity
5.1.3.1. Integration of Artificial Intelligence for Patient Matching & Monitoring
5.1.3.2. Growth in Emerging Markets with Expanding Digital Infrastructure
5.1.4. Impact Analysis
6. Strategic Insights and Industry Outlook
6.1. Market Leaders and Pioneers
6.1.1. Emerging Pioneers and Prominent Players
6.1.2. Established Leaders with the Largest Marketing Brand
6.1.3. Market Leaders with Established Products
6.2. Latest Developments and Breakthroughs
6.3. Regulatory and Reimbursement Landscape
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. South America
6.3.5. Middle East & Africa
6.4. Porter’s Five Forces Analysis
6.5. Supply Chain Analysis
6.6. Patent Analysis
6.7. SWOT Analysis
6.8. Unmet Needs and Gaps
6.9. Recommended Strategies for Market Entry and Expansion
6.10. Pricing Analysis and Price Dynamics
7. Decentralized Clinical Trials Market, By Study Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
7.1.2. Market Attractiveness Index, By Study Type
7.2. Interventional Trials*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Observational Trials
7.4. Expanded Access Trials
7.5. Others
8. Decentralized Clinical Trials Market, By Component
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
8.1.2. Market Attractiveness Index, By Component
8.2. Software Solutions*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Clinical Trial Management Systems
8.2.4. Electronic Data Capture Systems
8.2.5. Remote Patient Monitoring Systems
8.2.6. Others
8.3. Hardware Solutions
8.3.1. Smartphones and Tablets
8.3.2. Wearable Devices
8.3.3. Others
9. Decentralized Clinical Trials Market, By Therapeutic Area
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.1.2. Market Attractiveness Index, By Therapeutic Area
9.2. Oncology*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cardiovascular Diseases
9.4. Infectious Diseases
9.5. Respiratory Diseases
9.6. Neurology
9.7. Rare Diseases
9.8. Metabolic Disorders
9.9. Others
10. Decentralized Clinical Trials Market, By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Pharmaceutical and Biotechnology Companies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Contract Research Organizations
10.4. Academic and Research Institutes
10.5. Others
11. Decentralized Clinical Trials Market, By Regional Market Analysis and Growth Opportunities
12. Introduction
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.1. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. U.S.
12.2.7.2. Canada
12.2.7.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Germany
12.3.7.2. UK
12.3.7.3. France
12.3.7.4. Spain
12.3.7.5. Italy
12.3.7.6. Rest of Europe
12.4. Asia-Pacific
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.7.1. China
12.4.7.2. India
12.4.7.3. Japan
12.4.7.4. South Korea
12.4.7.5. Rest of Asia-Pacific
12.5. South America
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.7.1. Brazil
12.5.7.2. Argentina
12.5.7.3. Rest of South America
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13. Competitive Landscape and Market Positioning
14. Competitive Overview and Key Market Players
14.1. Market Share Analysis and Positioning Matrix
14.2. Strategic Partnerships, Mergers & Acquisitions
14.3. Key Developments in Product Portfolios and Innovations
14.4. Company Benchmarking
15. Company Profiles
15.1. ICON plc*
15.1.1. Company Overview
15.1.2. Product Portfolio
15.1.2.1. Product Description
15.1.2.2. Product Key Performance Indicators (KPIs)
16. Financial Overview
16.1. Company Revenue
16.1.1. Geographical Revenue Shares
16.1.1.1. Revenue Forecasts
16.1.2. Key Developments
16.1.2.1. Mergers & Acquisitions
16.1.2.2. Key Product Development Activities
16.1.2.3. Regulatory Approvals, etc.
16.1.3. SWOT Analysis
16.2. Parexel International Corporation
16.3. Laboratory Corporation of America Holdings
16.4. Medpace, Inc.
16.5. Science 37
16.6. THREAD, Inc.
16.7. Curebase
16.8. Castor
16.9. IQVIA Inc.
16.10. Medable Inc. (*LIST NOT EXHAUSTIVE)
17. Assumptions and Research Methodology
17.1. Data Collection Methods
17.2. Data Triangulation
17.3. Forecasting Techniques
17.4. Data Verification and Validation
18. Appendix
18.1. About Us and Services
18.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us